CQS Cayman’s Acorda Therapeutics ACOR Stock Holding History

CQS Cayman’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-254	Closed	-$809K	–	183
2015 Q3	$809K	Buy	+254	New	+$985K	0.07%	122

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CQS Cayman's ACOR Position: Q4 2015 in Review

CQS Cayman sold out of Acorda Therapeutics (ACOR) in Q4 2015, closing a stake of 254 shares — an estimated $809K sold.

CQS Cayman first reported a position in ACOR in Q3 2015 and held it in 1 quarter. The position peaked at $809K in Q3 2015. 186 funds tracked by Wall St. Rank hold ACOR as of Q4 2015.

CQS Cayman reported no remaining Acorda Therapeutics position as of Q4 2015 after selling out during the quarter.
CQS Cayman sold 254 Acorda Therapeutics shares in Q4 2015, an estimated $809K.
CQS Cayman first reported a position in Acorda Therapeutics in Q3 2015 and held it in 1 quarter.
CQS Cayman's Acorda Therapeutics position peaked at $809K in Q3 2015.
186 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2015.

Based on CQS Cayman's 13F filing for Q4 2015, filed 11 Feb 2016.